July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Tau dysfunction in glaucoma: modulation of optic nerve axonal transport via gene therapy
Author Affiliations & Notes
  • Tasneem Khatib
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, ENGLAND, United Kingdom
    Eye Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
  • Andrew Osborne
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, ENGLAND, United Kingdom
    Quethera Ltd, Cambridge, United Kingdom
  • Peter S Widdowson
    Quethera Ltd, Cambridge, United Kingdom
  • Keith R Martin
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, ENGLAND, United Kingdom
    Eye Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
  • Footnotes
    Commercial Relationships   Tasneem Khatib, None; Andrew Osborne, QUETHERA Ltd (F); Peter Widdowson, QUETHERA Ltd (I), QUETHERA Ltd (P); Keith Martin, QUETHERA Ltd (I), QUETHERA Ltd (C), QUETHERA Ltd (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3716. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tasneem Khatib, Andrew Osborne, Peter S Widdowson, Keith R Martin; Tau dysfunction in glaucoma: modulation of optic nerve axonal transport via gene therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3716.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Disruption of axonal transport (AT) in retinal ganglion cells (RGCs) is a hallmark of glaucomatous optic neuropathy. Tau hyperphosphorylation (TauH), with subsequent loss of microtubule stability and formation of neurotoxic aggregates may contribute to this AT impairment. We assessed pathological TauH in experimental glaucoma and whether optic nerve AT (ONAT) can be modulated in a mouse model of tauopathy by overexpressing mature BDNF (mBDNF) and its receptor TrkB through an AAV2 viral vector (TrkB-2A-mBDNF; QTA020V).

Methods : Sprague Dawley rats underwent laser induced intraocular pressure (IOP) elevation. IOP and the RGC-specific positive scotopic threshold response (pSTR) were assessed at multiple timepoints and tissue processed for TauH quantification. To assess modulation of optic nerve AT in a mouse model of tauopathy, 4-month old mice homozygous for human mutant P301S tau were injected intravitreally with AAV2 TrkB mBDNF. Cholera toxin B (CTB) was administered 1 month later with tissue collection 24 hours post CTB injection. ONAT was quantified by measuring CTB intensity at 100 µm intervals.

Results : Pathological TauH at the AT8 epitope was elevated by 4.5-fold at 2 days (p=0.007) and 2-fold at 1 month (p=0.07) in our experimental glaucoma model, and elevated 2.5-fold at 1 month at the PHF-1 epitope (p=0.01). Early post-injury, there was a 3-fold increase in the inactive form of tau protein kinase GSK3B (p=0.025) but this did not persist. There were no changes in the pSTR response. Injection of AAV2-GFP itself did not affect retinal TauH relative to PBS or naïve controls. Administration of AAV2 TrkB mBDNF resulted in a 2.6-fold increase in proximal optic nerve AT (p<0.0001). This correlated with a reduction in both the AT8 and PHF-1 immunoreactivity in the optic nerve, while total tau remained unchanged.

Conclusions : Pathological TauH occurs following IOP elevation, the strongest risk factor for glaucoma progression. Regulation of phosphorylation via increased inactivation of the tau protein kinase GSK3B appears in the early response to injury but this negative regulation is subsequently lost. These changes may contribute to disruption of AT in glaucoma. Administration of BDNF and TrkB via an RGC-specific viral vector improves ONAT in a tauopathy model. Studies are ongoing to assess the efficacy of our construct on AT and TauH when administered in an experimental glaucoma model.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×